Khushali Jhaveri/LinkedIn
Jun 20, 2025, 16:26
Khushali Jhaveri Shares Epcoritamab Combination Results in First-Line DLBCL
Khushali Jhaveri, , shared a post on X:
“Bispecifics in the frontline?
In EPCORE NHL-5, Epcoritamab + pola-R-CHP in 1L DLBCL:
ORR 100%, CRR 97%
81% MRD– by C3D1 (ctDNA!)
Durable, deep responses. No ICANS. All CRS low grade.
Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% decreased risk of progression and 80% decreased risk of death.
CR rate: 92.8% vs 67.1%.
Small N, but a strong signal.”
Raul Cordoba, Chair of Community Stakeholder Committee at European Hematology Association (EHA), shared this post, adding:
“Impressive results!! We will need to wait for further follow-up to see the DoR. Great job!”
More posts featuring Khushali Jhaveri.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 20, 2025, 16:26
Jun 20, 2025, 16:17
Jun 20, 2025, 16:16
Jun 20, 2025, 16:02
Jun 20, 2025, 15:31